ROIV Roivant Sciences Ltd. stock chart & analysis
Conviction 31HealthcareScan · Fri, Nov 6, 2026Roivant Sciences Ltd. (ROIV) closed at $38.88 (+6.17%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 60, RS Rating 96, -8.4% from its 52-week high, +79.3% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Tue, Jun 30, 2026 · quarterly.
ROIV technical analysis
Trend
ROIV is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 6.1% above the 50-day ($36.69) and 22.2% above the 200-day ($31.85). ADX(14) at 15 points to a weak trend — more range than direction. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 60, in the bullish half of its range. The MACD histogram is positive. A bearish RSI divergence is in place. Its RS Rating of 96 puts its weighted 12-month performance ahead of about 96% of the US market.
Volume and volatility
Volume on the latest session ran 1.6× its 20-day average. It trades about $271.9M a day on average. ATR(14) is $1.52, 3.9% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (-0.12) shows distribution.
Key levels
The chart pattern's support is $33.16 and its resistance $38.49. The 52-week range is $19.79 to $42.50; price is 8.4% below the high and 96.6% above the low. The VWAP anchored at the 52-week high is $37.68, below price.
Performance
ROIV returned +5.4% (1 week), +13.8% (1 month), +8.8% (3 months), +36.3% (6 months), +92.4% (1 year), +79.3% (year to date).
About Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Pharmaceutical Preparations · Listed 2021 · 721 employees
Recent news
- Under a trading plan, Eric Venker sold 200,000 Roivant Sciences (ROIV) shares.Stock Titan · Thu, Nov 5, 2026
- Roivant Sciences Ltd.: Ownership stake amendedSEC EDGAR · Thu, Nov 5, 2026
- Roivant Sciences (ROIV) Stock Looks Expensive Against Its Book ValueYahoo Finance · Thu, Nov 5, 2026
Congress activity
Disclosed STOCK Act trades in ROIV · 3 recent
Insider activity
SEC Form 4 transactions in ROIV · open-market 4 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Venker Eric President & Immunovant CEO · Common Shares · 2026-11-03 | Sell | 200K | $7.3M | 2026-11-03 | 2026-11-05 |
Venker Eric President & Immunovant CEO · Common Shares · 2026-10-28 | Sell | 200K | $7.3M | 2026-10-28 | 2026-10-30 |
MOMTAZEE JAMES C Director · Common Shares · 2026-10-23 | Grant | 383 | — | 2026-10-23 | 2026-10-27 |
MOMTAZEE JAMES C Director · Common Shares · 2026-10-23 | Tax | 77 | $3K | 2026-10-23 | 2026-10-27 |
Oren Ilan Director · Common Shares · 2026-10-23 | Grant | 810 | — | 2026-10-23 | 2026-10-27 |
Epperly Melissa B, Director · Common Shares · 2026-10-23 | Grant | 513 | — | 2026-10-23 | 2026-10-27 |
Epperly Melissa B, Director · Common Shares · 2026-10-23 | Tax | 116 | $4K | 2026-10-23 | 2026-10-27 |
Epperly Melissa B, Director · Common Shares · 2026-10-01 | Exercise | 17.75K | $79K | 2026-10-01 | 2026-10-05 |
Epperly Melissa B, Director · Common Shares · 2026-10-01 | Sell | 16.85K | $608K | 2026-10-01 | 2026-10-05 |
Epperly Melissa B, Director · Common Shares · 2026-10-01 | Sell | 900 | $33K | 2026-10-01 | 2026-10-05 |
SEC filings
EDGAR filings in ROIV · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.